« Return to News | Clinical Intelligence

Eisai reports new data on Halaven

Tuesday, March 8, 2011 10:24 AM

Eisai, based in Japan, reported new data confirming its marine-derived drug Halaven improves overall survival in women with late-stage breast cancer. 

Data from the 762-patient phase III Embrace trial has been published in The Lancet and demonstrates that Halaven (eribulin) improved overall survival compared with treatment of physician’s choice (TPC) in women with metastatic breast cancer previously treated with at least an anthracycline and a taxane. TPC is defined as any single-agent chemotherapy, hormonal treatment or biologic approved for cancer, palliative treatment or radiotherapy.

Embrace met its endpoint, demonstrating a statistically significant increase in OS for Halaven compared with TPC of 2.5 months (13.1 vs 10.6 months respectively). The drug was approved by the FDA last November. The most common adverse events in both arms were fatigue (53.7% with Halaven, 39.7% with TPC) and neutropaenia (51.7% vs 29.6%).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.